MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 222 filers reported holding MIRATI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.61 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45 | +9.8% | 1,040 | -16.1% | 0.01% | -16.7% |
| Q2 2023 | $41 | -10.9% | 1,240 | -28.7% | 0.01% | +20.0% |
| Q1 2023 | $46 | -82.6% | 1,740 | -86.2% | 0.01% | -77.3% |
| Q4 2022 | $264 | -99.6% | 12,600 | +90.3% | 0.02% | +340.0% |
| Q3 2022 | $74,000 | -71.2% | 6,620 | -19.8% | 0.01% | -72.2% |
| Q2 2022 | $257,000 | +1876.9% | 8,250 | +129.2% | 0.02% | +1700.0% |
| Q1 2022 | $13,000 | -99.0% | 3,600 | -90.0% | 0.00% | -98.1% |
| Q4 2021 | $1,279,000 | -65.8% | 35,867 | -68.3% | 0.05% | -68.6% |
| Q3 2021 | $3,745,000 | – | 113,243 | +3331.6% | 0.17% | – |
| Q2 2021 | $0 | -100.0% | 3,300 | -69.7% | 0.00% | -100.0% |
| Q1 2021 | $35,000 | -91.2% | 10,900 | -42.5% | 0.00% | -89.5% |
| Q4 2020 | $396,000 | +17.5% | 18,968 | +17.4% | 0.02% | -9.5% |
| Q3 2020 | $337,000 | -4.0% | 16,163 | +10.7% | 0.02% | -8.7% |
| Q2 2020 | $351,000 | +21.5% | 14,604 | -72.6% | 0.02% | +53.3% |
| Q1 2020 | $289,000 | -79.4% | 53,300 | +28.1% | 0.02% | -82.8% |
| Q4 2019 | $1,401,000 | +119.6% | 41,606 | -19.4% | 0.09% | +47.5% |
| Q3 2019 | $638,000 | -42.3% | 51,600 | +4.1% | 0.06% | -42.2% |
| Q2 2019 | $1,106,000 | +455.8% | 49,550 | +77.0% | 0.10% | +385.7% |
| Q1 2019 | $199,000 | +485.3% | 28,000 | +409.0% | 0.02% | +600.0% |
| Q4 2018 | $34,000 | -96.8% | 5,501 | -94.8% | 0.00% | -96.0% |
| Q3 2018 | $1,068,000 | +936.9% | 106,000 | +332.7% | 0.08% | +837.5% |
| Q2 2018 | $103,000 | +145.2% | 24,500 | +1121.3% | 0.01% | +166.7% |
| Q1 2018 | $42,000 | -23.6% | 2,006 | -92.4% | 0.00% | +50.0% |
| Q4 2017 | $55,000 | -79.6% | 26,500 | -29.3% | 0.00% | -80.0% |
| Q3 2017 | $270,000 | +474.5% | 37,500 | +125.4% | 0.01% | +400.0% |
| Q2 2017 | $47,000 | -89.2% | 16,640 | -83.8% | 0.00% | -89.5% |
| Q1 2017 | $435,000 | +637.3% | 102,513 | +465.1% | 0.02% | +850.0% |
| Q4 2016 | $59,000 | +59.5% | 18,140 | +154.1% | 0.00% | 0.0% |
| Q3 2016 | $37,000 | +48.0% | 7,140 | +38.9% | 0.00% | +100.0% |
| Q2 2016 | $25,000 | -62.7% | 5,140 | +63.7% | 0.00% | -75.0% |
| Q1 2016 | $67,000 | -50.7% | 3,140 | -46.2% | 0.00% | -42.9% |
| Q4 2015 | $136,000 | – | 5,840 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $116,595,216 | 81.37% |
| ORACLE INVESTMENT MANAGEMENT INC | 201,400 | $7,488,052 | 7.25% |
| Paradigm Biocapital Advisors LP | 1,396,779 | $51,932,243 | 4.92% |
| Octagon Capital Advisors LP | 750,000 | $27,885,000 | 4.01% |
| Boxer Capital, LLC | 2,000,000 | $74,360 | 3.65% |
| Artal Group S.A. | 1,537,709 | $57,172 | 3.40% |
| Avoro Capital Advisors LLC | 5,555,555 | $206,555,535 | 3.06% |
| RTW INVESTMENTS, LP | 3,643,114 | $135,450,979 | 2.82% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 244,000 | $9,071,920 | 2.53% |
| Kynam Capital Management, LP | 499,853 | $18,584,535 | 2.40% |